Kytril -->

Good day,
Good night,
Good morning

1 mg or 2 mg tablets and 1 mg/1 ml or 3 mg/3 ml solutions for injection

For acute nausea and vomiting in adults associated with:
CINV = Chemotherapy Induced Nausea & Vomiting1-4
RINV = Radiotherapy Induced Nausea & Vomiting1-4
PONV = Post-Operative Nausea & Vomiting3,4

A long half-life is the key to Kytril’s lasting action1–5

  • Ondansetron IV: half-life 4 hours – duration of effect of 12–24 hours5
  • Kytril IV: half-life 9 hours3-5 – duration of effect of more than 24 hours5
IV = Intravenous

When they need it most in CINV6

In patients receiving highly emetogenic chemotherapy including cisplatin6

Kytril 3 mg/ml IV or ondansetron 8 mg IV, plus dexamethasone 8 mg IV immediately prior to therapy.
Oral dexamethasone 4 mg three times a day on days 2 to 4 of therapy (n=21). Double-blind crossover study.6
Kytril “...is significantly better on day 2 when the majority of patients suffer most.“ 6
  • Palonosetron 0.25 mg IV and Kytril 1 mg/ml IV have similar effects on delayed nausea7
IV = Intravenous    CINV = Chemotherapy Induced Nausea & Vomiting

Kytril oral tablets offer reliable, lasting control in RINV8

Patients receiving hyperfractionated total body irradiation (TBI)
over a 4-day period8

p <0.01 vs. historic control for both treatment groups8
  • The proportion of patients with >5 emetic episodes over the 4 days was significantly less in the Kytril group (0%; p<0.01) but not in the ondansetron group (20%), vs. the control group (55.6%)8
Kytril 2 mg/ml (administered as two 1 mg tablets, n=18) was given once daily, 1 h prior to the administration of the first daily fraction of radiation. Ondansetron 8 mg (n=15) was given 1.5 h prior to every fraction of radiation (three times daily for days 0 to 3 and twice daily on day 4). Control did not receive a 5-HT3-receptor antagonist, (n=90)8. All patients had a diagnosis of either malignant disease or aplastic anaemia, and were hospitalised to receive 11 fractions each of 120 cGy of radiation over the course of 4 days for a total radiation exposure of 1320 cGy prior to bone marrow transplantation and the initiation of any conditioning chemotherapy.8
IV = Intravenous    RNIV = Radiotherapy Induced Nausea & Vomiting

Kytril IV controls PONV throughout the whole day9

Patients undergoing surgical procedures with spinal anaesthesia9

  • Kytril was significantly more effective in the late postoperative period (3-24 hours)9
  • A complete response (absence of nausea and vomiting) was seen in significantly more Kytril patients (86.7%, p<0.05) than ondansetron patients (60%)9
Patients undergoing gynaecological surgical procedures under spinal anaesthesia were randomised to two groups (each n=30): Kytril 2 mg/ml IV or ondansetron 4 mg IV 5 minutes before induction of anaesthesia9
IV = Intravenous    PONV = Post-Operative Nausea & Vomiting

Kytril has good tolerability1–4

  • The most commonly reported adverse reactions for Kytril (≥ 1/10) are headache and constipation, which may be transient
  • ECG changes including QT prolongation have been reported with Kytril and with other 5-HT3 antagonists
  • Other adverse events –
    Common (1/100 to <1/10): insomnia, diarrhoea, elevated hepatic transaminases (occurred at similar frequency to comparator therapy)
    Uncommon (1/1,000 to <1/100): hypersensitivity reactions, e.g. anaphylaxis, urticaria, extrapyrimidal reactions, serotonin syndrome, rash

References

Downloads

Contact Us

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to ATNAHS Pharma UK Ltd on 00 44 (0) 1279 406759, or by email to atnahspv@diamondservices.com